The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...
The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...
R&,D outsourcing involves pharmaceutical companies subcontracting parts of their R&,D efforts to third-party service providers. Small or mid-sized pharmaceutical or biotech houses may use ...
is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. That was one of the key messages from SynBioBeta’s Synthetic Biology Biopharma Conference last month ...
Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...
In addition to a continued focus on growing drug pipelines, and the increasing use of artificial intelligence (AI) and data ...
The Inflation Reduction Act was passed in 2021 to reduce the government deficit, incentivize domestic energy production, and ...
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, ...
This $2.5 billion investment reflects AstraZeneca's belief in "the world-class life sciences ecosystem in Beijing" and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback